Prevention of Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
Paclitaxel-induced peripheral neuropathy (PIPN) is one of the most dose-limiting side
effects; it causes patients discomfort and pain and sometimes causes the termination of the
chemotherapy cycles, leading to treatment failure. A lot of interventions have been tried to
prevent PIPN, ensure complete administration of the chemotherapy cycles, and increase the
survival rate. One of the promising interventions in the prevention of PIPN is Losartan.
Losartan is an angiotensin receptor blocker (ARBs) and is used to treat hypertensive
patients. There is strong evidence from different preclinical studies and retrospective
cohort studies that Losartan has a neuroprotective effect.
The purpose of our study is to investigate the efficacy of Losartan in the prevention of
peripheral neuropathy associated with Paclitaxel treatment in Breast Cancer patients.